2025 Surgery Grand Rounds | Advanced Thyroid Cancer Treatment Neoadjuvant Therapy

Duarte, CA US
May 22, 2025

A significant deficit in neoadjuvant therapy for advanced thyroid cancer stems from limited guidelines and inconsistent use of systemic therapies, resulting in suboptimal outcomes. Clinicians face an educational gap in understanding indications, protocols, and multidisciplinary strategies for integrating these therapies effectively. Current practices rely heavily on surgery and adjuvant treatments, whereas ideal care would include well-defined neoadjuvant approaches to enhance resectability and improve prognosis.

A lecture on neoadjuvant therapy for thyroid cancer is necessary to address the lack of standardized guidelines and the limited adoption of systemic therapies in managing advanced cases. The gap exists due to insufficient clinical trials, variable awareness among providers, and the historical reliance on surgery and adjuvant treatments as primary modalities. By educating clinicians on emerging evidence and multidisciplinary strategies, this lecture can promote more consistent and effective integration of neoadjuvant therapy into clinical practice.
 

Target Audience

Department of Surgery Faculty, Fellows, Visiting Residents and Staff.

Learning Objectives

  • Analyze the existing limitations in guidelines and clinician awareness that contribute to the underutilization of neoadjuvant approaches.
  • Integrate emerging evidence and case studies to guide the use of systemic therapies and multidisciplinary planning in clinical practice.
  • Promote engagement in clinical trials and collaborative efforts to establish standardized protocols for neoadjuvant therapy in thyroid cancer care.
  • Identify the indications, mechanisms, and potential benefits of neoadjuvant therapy in the management of advanced thyroid cancer.
  • Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Activity summary
Available credit: 
  • 1.00 ABS Accredited CME
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2025 Surgery Grand Rounds | Advanced Thyroid Cancer Treatment Neoadjuvant Therapy for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Activity opens: 
05/22/2025
Activity expires: 
05/23/2025
Event starts: 
05/22/2025 - 7:00am PDT
Event ends: 
05/22/2025 - 8:00am PDT
Add to calendar: 
City of Hope
1500 E Duarte Rd
Duarte, CA 91010
United States

Virtual Meeting- Zoom

Gregory W. Randolph, MD, FACS, FACE, FEBS (Endocrine), MAMSE  Professor of Otolaryngology Head and Neck Surgery; Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology, Harvard Medical School; Chief Thyroid/Parathyroid Endocrine Surgical Division, Department of Otolaryngology Head and Neck Surgery, Massachusetts Eye and Ear Infirmary; International Thyroid Oncology Group (ITOG) President; American College of Surgeons Otolaryngology Governor

Presenter: Dr. Randolph has indicated the following relevant financial relationships: Consultant for Getinge and Medtronic; Grant/Research Support from Eisai, Getinge, and Medtronic.

Planner: Yuman Fong, MD has indicated the following relevant financial relationships:Consultant for Eureka, Imugene, Medtronics, Theromics, Vergent Bioscience and XDemics; Stock/Shareholder (publicly owned companies) of Imugene, Iovance, and XDemics; Other financial/material interests (royalties) in Imugene and XDemics.

he educational content has been peer-reviewed, an attestation on file and no conflicts were noted.

CME Committee/Reviewer no relevant financial relationships:  Daneng Li, MD

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement of the American Board of Surgery's Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit. 

 

The following credit type(s) are being offered for this course:

•  AMA PRA Category 1 Credit™  1.0

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.

Available Credit

  • 1.00 ABS Accredited CME
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2025 Surgery Grand Rounds | Advanced Thyroid Cancer Treatment Neoadjuvant Therapy for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Please login or register to take this activity.